drug
crisaborole
Marketedupdated 3mo agoby $PFE PFIZER INC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying crisaborole
- phase4Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis
- phase4Steroid-reducing Effects of Crisaborole
- phase2Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo
- EP1Characterizing Skin Microbiome Change in Atopic Dermatitis
- —Wearable Skin Sensors to Assess Nocturnal Scratch Behavior
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 16, 2027
176 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Jul 20, 2030patentUS 8168614*PED3.9y
- Jan 20, 2030method-of-use (U-1932)US 81686143.4y
- Dec 29, 2029patentUS 8039451*PED3.4y
- Jun 29, 2029compositionUS 80394512.8y
- Aug 16, 2027patentUS 8501712*PED357d
- Aug 16, 2027patentUS 9682092*PED357d
- Feb 16, 2027method-of-use (U-1932)US 8501712176d
- Feb 16, 2027method-of-use (U-1932)US 9682092176d
FDA exclusivities (1)
- Apr 3, 2026D-191New Indication (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 12m ago
Found something off?
comments(0)
5-min edit window · permanent after that